Yansheng Du

Dr. Yansheng Du

Indiana University School of Medicine

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
YDYansheng Du
Yansheng Du
RDR. Dodel
R. Dodel
HHH. Hampel
H. Hampel
KBK. Buerger
K. Buerger
SLS. Lin
S. Lin
SPS. Paul
S. Paul
Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ1–42) and administration of antibodies against Aβ into amyloid precursor protein APPV717F– transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.

1 February 2009 in Stem Cells
Verified
Journal Article
Open access
PDF file
XWXing Wei
Xing Wei
ZDZhimei Du
Zhimei Du
LZLiming Zhao
Liming Zhao
DFDongni Feng
Dongni Feng
GWGang Wei
Gang Wei
YDYansheng Du
Yansheng Du
Adipose tissue stroma contains a population of mesenchymal stem cells, which support repair when administered to damaged tissues, in large part through secreted trophic factors. We directly tested the ability of media collected from cultured adipose-derived stem cells (ASCs) to protect neurons in a rat model of brain hypoxic-ischemic (HI) injury. Concentrated conditioned medium from cultured rat ASCs (ASC-CM) or control medium was infused through the jugular vein of neonatal Sprague-Dawley rats subjected to HI injury. The ASC-CM was administered either 1 hour before or 24 hours after induction of injury. Analysis at 1 week indicated that administration at both time points significantly protected against hippocampal and cortical volume loss. Analysis of parallel groups for behavioral and learning changes at 2 months postischemia demonstrated that both treated groups performed significantly better than the controls in Morris water maze functional tests. Subsequent post-mortem evaluation of brain damage at the 2-month time point confirmed neuronal loss to be similar to that observed at 1 week for all groups. We have identified several neurotrophic factors in ASC-CM, particularly insulin-like growth factor-1 and brain-derived neurotrophic factor, which are important factors that could contribute to the protective effects of ASCs observed in studies with both in vitro and in vivo neuronal injury models. These data suggest that delivery of the milieu of factors secreted by ASCs may be a viable therapeutic option for treatment of HI, as well as other brain injuries.

23 July 2002 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RDRichard Dodel
Richard Dodel
HHHarald Hampel
Harald Hampel
CDCandan Depboylu
Candan Depboylu
SLSuizhen Lin
Suizhen Lin
FGFeng Gao
Feng Gao
YDYansheng Du
Yansheng Du

1 September 2003 in Brain
Verified
Journal Article
Open access
PDF file
YDYansheng Du
Yansheng Du
XWXing Wei
Xing Wei
RDRichard Dodel
Richard Dodel
NSNorbert Sommer
Norbert Sommer
HHHarald Hampel
Harald Hampel
MFMartin Farlow
Martin Farlow
The accumulation of β‐amyloid (Aβ) in neuritic plaques is thought to be causative for the progression of Alzheimer’s disease (AD). Recently, both active immunization and passive administration of Aβ antibodies dramatically attenuated amyloid plaque deposition, neuritic dystrophy, astrogliosis and behaviour deficits in transgenic animals. In addition, we and others have found that titres of naturally occurring anti‐Aβ antibodies in the CSF of AD patients are significantly lower than those in age‐matched controls. Treatment with intravenous immunoglobulins (a preparation that contained anti‐Aβ antibodies) significantly lowered CSF levels of Aβ in non‐demented patients. In this study, anti‐Aβ antibodies were isolated from immunoglobulin preparations and these anti‐Aβ antibodies strongly block fibril formation or disrupt formation of fibrilar structures. Furthermore, these antibodies almost completely prevented neurotoxicity of Aβ. In contrast, immunoglobulins depleted of anti‐Aβ antibodies had little effect on Aβ fibril formation or protection of neuronal cells. This study supports the findings that human anti‐Aβ antibodies may interfere with the pathogenesis of AD by more than one mechanism, and administration of polyclonal human anti‐Aβ antibodies isolated from plasma is a potential therapeutic agent to prevent or slow down disease progression.

6 October 2004 in Brain
Verified
Journal Article
Open access
PDF file
XWXing Wei
Xing Wei
LZLiming Zhao
Liming Zhao
ZMZhizhong Ma
Zhizhong Ma
DHDavid M. Holtzman
David M. Holtzman
CYChong Yan
Chong Yan
YDYansheng Du
Yansheng Du
Neonatal hypoxic–ischaemic (HI) brain injury resulting in encephalopathy is a leading cause of morbidity and mortality with no effective treatment. Here we show that caffeic acid phenethyl ester (CAPE), an active component of propolis, administered either before or after an HI insult, significantly prevents HI-induced neonatal rat brain damage in the cortex, hippocampus and thalamus. In addition to blocking HI-induced caspase 3 activation, CAPE also inhibits HI-mediated expression of inducible nitric oxide synthase and caspase 1 in vivo and potently blocks nitric oxide-induced neurotoxicity in vitro. Furthermore, CAPE directly inhibits Ca2+-induced cytochrome c release from isolated brain mitochondria. Thus, CAPE induces neuroprotection against HI-induced neuronal death, possibly by blocking HI-induced inflammation and/or directly inhibiting the HI-induced neuronal death pathway. CAPE may therefore be a novel effective therapy for preventing neonatal HI injury.

22 January 2005 in Neuroscience
Verified
Journal Article
Closed access
XWX. Wei
X. Wei
LZL. Zhao
L. Zhao
JLJ. Liu
J. Liu
RDR.C. Dodel
R.C. Dodel
MFM.R. Farlow
M.R. Farlow
YDYansheng Du
Yansheng Du